HIGHLIGHTS OF PRESCRIBING INFORMATION These …
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KESIMPTA safely and effectively. See full prescribing information for KESIMPTA. or live vaccines is not recommended during treatment with KESIMPTA® (ofatumumab) injection, for subcutaneous use Initial U.S. Approval: 2009
Download HIGHLIGHTS OF PRESCRIBING INFORMATION These …
Information
Domain:
Source:
Link to this page:
Documents from same domain
HIGHLIGHTS OF PRESCRIBING INFORMATION CAR-positive …
www.novartis.usSee full prescribing information for complete boxed warning. • Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving KYMRIAH. Do not administer KYMRIAH to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with
Enrollment Application for the Novartis Patient Assistance ...
www.novartis.usVOTRIENT® (pazopanib) tablets ZOMETA® (zoledronic acid) for injection ZORTRESS® (everolimus) ZYKADIA® (ceritinib) capsules *Additional products may be available. Please check the NPAF website at www.pap.novartis.com for the …
ADAKVEO. ADAKVEO HIGHLIGHTS OF PRESCRIBING …
www.novartis.usPregnancy: May cause fetal harm. (See 17 for PATIENT COUNSELING INFORMATION and FDA-8.1) approved patient labeling. Revised: 7/2021 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 2.1 Recommended Dosage 2.2 Preparation and Administration 2.3 Management of Infusion …
MAYZENT. treatment and if there is any change in vision ...
www.novartis.usTest patients for antibodies to varicella zoster virus (VZV) before initiating MAYZENT; VZV vaccination of antibody-negative patients is recommended prior to commencing treatment with MAYZENT [see Warnings and Precautions (5.1)]. Liver Function Tests
Instructions - Novartis United States of America
www.novartis.usI consent to receive marketing calls and texts from and on behalf of NPAF, made with an auto dialer or prerecorded voice, at the phone number(s) provided. I understand that my consent is not required or a condition of purchase. Number of messages will vary based on your program selections. Message and data rates may apply.
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
www.novartis.usacute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. (1.4) ... Reports of motor vehicle accidents have been received in patients receiving Gleevec. Caution patients about driving a car or operating machinery. (5.13) Renal Toxicity. A decline in renal function may occur in patients receiving
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
www.novartis.usPancreatitis and Elevated Serum Lipase: Monitor serum lipase; if elevations are accompanied by abdominal symptoms, interrupt doses and consider appropriate diagnostics to exclude pancreatitis. (5.5) Hepatotoxicity: Monitor hepatic function tests monthly or …
prescribing information for AFINITOR/AFINITOR DISPERZ ...
www.novartis.uswith sunitinib or sorafenib. (1.3) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. (1.4) AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of adult and …
COSENTYX (secukinumab) injection, for subcutaneous use o ...
www.novartis.usCOSENTYX is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation. 1.5 Enthesitis-Related Arthritis COSENTYX is indicated for the treatment of active enthesitis-related arthritis (ERA) in patients 4 years of age and older.
Novartis Patient assistance Foundation Application
www.novartis.us• Patient Section 5: We need you to read the Patient Authorization page to allow us to process your application, communicate with you and manage your enrollment. Please read, sign and date at the bottom of the Patient Application. Lastly, work with your health care provider (HCP) to complete his/her sections of the application. If you
Related documents
HIGHLIGHTS OF PRESCRIBING INFORMATION • These …
labeling.bayerhealthcare.comHIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights do not include all the information needed to use SKYLA safely and effectively. See full prescribing information for SKYLA. SKYLA (levonorgestrel-releasing intrauterine system) Initial U.S. Approval: 2000 •---- …
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
labeling.bayerhealthcare.comHIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights do not include all the information needed to use MIRENA safely and effectively. See full prescribing information for MIRENA. MIRENA (levonorgestrel-releasing intrauterine system) Initial U.S. Approval: 2000 ---- …
HIGHLIGHTS OF PRESCRIBING INFORMATION Treatment …
docs.boehringer-ingelheim.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PRADAXA Capsules safely and effectively. See full prescribing information for PRADAXA Capsules. PRADAXA® (dabigatran etexilate) capsules, for oral use Initial U.S. Approval: 2010 WARNING: (A) PREMATURE DISCONTINUATION OF PRADAXA
HIGHLIGHTS OF PRESCRIBING INFORMATION ...
docs.boehringer-ingelheim.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JARDIANCE safely and effectively. See full prescribing information for JARDIANCE. JARDIANCE® (empagliflozin tablets), for oral use Initial U.S. Approval: 2014 ---- …
HIGHLIGHTS OF PRESCRIBING INFORMATION thereafter …
docs.boehringer-ingelheim.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use OFEV safely and effectively. See full prescribing information for OFEV. OFEV® (nintedanib capsules), for oral use Initial U.S. Approval: 2014 -----RECENT MAJOR CHANGES-----
HIGHLIGHTS OF PRESCRIBING INFORMATION • These …
labeling.bayerhealthcare.comHIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights do not include all the information needed to use SKYLA safely and effectively. See full prescribing information for SKYLA. SKYLA (levonorgestrel-releasing intrauterine system) Initial U.S. Approval: 2000 •-----RECENT MAJOR CHANGES-----
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
media.allergan.comAug 29, 2017 · HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LATISSE safely and effectively. See full prescribing information for LATISSE. LATISSE® (bimatoprost ophthalmic solution) 0.03%, for topical ophthalmic use Initial U.S. Approval: 2001 _____INDICATIONS AND USAGE_____
HIGHLIGHTS OF PRESCRIBING INFORMATION • These …
qsymia.comHIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights do not include all the information needed to use QSYMIA ® safely and effectively. See full prescribing information for QSYMIA. QSYMIA (phentermine and topiramate extended-release) capsules, for oral use, CIV . Initial U.S. Approval: 2012 .
DOSAGE AND ADMINISTRATION HIGHLIGHTS OF …
solirispro.comThese highlights do not include all the information needed to use SOLIRIS safely and effectively. See full prescribing information for SOLIRIS. SOLIRIS® (eculizumab) injection, for intravenous use Initial U.S. Approval: 2007 WARNING: SERIOUS MENINGOCOCCAL INFECTIONS See full prescribing information for complete boxed warning
HIGHLIGHTS OF PRESCRIBING INFORMATION These …
www.alnylam.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ONPATTRO® safely and effectively. See full prescribing information for ONPATTRO. ONPATTRO (patisiran) lipid complex injection, for intravenous use Initial U.S. Approval: 2018 -----RECENT MAJOR CHANGES-----
Related search queries
HIGHLIGHTS OF PRESCRIBING INFORMATION • These, HIGHLIGHTS OF PRESCRIBING INFORMATION • These highlights, Information, Prescribing information, HIGHLIGHTS OF PRESCRIBING INFORMATION These, HIGHLIGHTS OF PRESCRIBING INFORMATION, HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights, QSYMIA, HIGHLIGHTS OF, These highlights